A team of researchers from the University of Iowa has unveiled concerns about the use of semaglutide, a widely prescribed GLP-1 receptor agonist for type 2 diabetes and obesity, in patients with neuroendocrine neoplasms (NENs)
ERG deregulation induces IGF-1R expression in prostate cancer cells and affects sensitivity to anti-IGF-1R agents
The close votes reflect this central tension: whether controlled access through traditional compounding may reduce some real-world risks even when the evidence base remains incomplete
The same FDA document mandates post-marketing trials to demonstrate that the novel agent does not increase cardiovascular risk by more than 30% compared to placebo (henceforth these trials were named cardiovascular outcome trial), if premarketing studies did not already demonstrate this
However, the role of -MSH and its possible target receptors in the heart remain completely unknown
Modern pen injector platforms offer: customizable dosing systems compatibility with standard drug cartridges patient-centered design scalable manufacturing for commercial drug products These features make injection pens a preferred solution for delivering peptide and biologic therapies